News
Apnimed to Participate in the 2023 BIO International Convention
May 23, 2023
June 5-8, 2023 at the Boston Convention & Exhibit Center
Apnimed Presented Positive Phase 2b Results on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea, for the First Time at ATS 2023
May 21, 2023
New MARIPOSA Study Data Showed AD109 Statistically Significantly Improved
Both Objective and Subjective Outcomes in OSA Patients
Apnimed to Present Positive Phase 2b Results on AD109, an Investigational Oral Treatment for Obstructive Sleep Apnea, at ATS 2023
May 15, 2023
– New MARIPOSA Data Showing AD109 Had Statistically Significant Improvement in Both Objective and Subjective Outcomes to Be Featured as an Oral Presentation in the Breaking News in OSA: New Approaches and New Trials Mini Symposium – Data Supporting Use of Specific...
Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference
Apr 10, 2023
The corporate presentation will be on April 17, 2023, from 9:30 -10:10 am ET in Track 2.
Apnimed to Participate in the SVB Securities Global Biopharma Conference
Jan 25, 2023
1×1 investor meetings will take place virtually January 31- February 2, 2023
Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing to Fund Two Planned Phase 3 Trials of AD109, an Oral Medication with the Potential to Be the First Therapy for Direct Treatment of Obstructive Sleep Apnea (OSA)
Jan 3, 2023
Phase 3 Trials Expected to Begin Enrollment in Second Quarter of 2023, Subject to Discussions with the FDA
Apnimed to Present at the Stifel Healthcare Conference
Nov 8, 2022
Apnimed management will participate in the conference taking place November 15-16, 2022 in New York.
Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109, Drug Candidate with the Potential to be the First Oral Therapy for Obstructive Sleep Apnea (OSA)
Oct 17, 2022
--AD109 Achieved the Primary Endpoint of Reduced Nighttime Airway Obstruction --AD109 Significantly Improved Daytime Impairment Caused by OSA --AD109 Was Well-Tolerated CAMBRIDGE, Mass. October 17, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on...
Apnimed to Participate in the 2nd Annual Needham Biotech Private Company Virtual 1×1 Forum
Oct 12, 2022
CAMBRIDGE, Mass October 12, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to treat obstructive sleep apnea (OSA) and related disorders, including its lead candidate AD109, today announced that company...
Apnimed Expands Senior Leadership Team by Appointing John Cronin, MD, Senior Vice President, Clinical Development
Oct 5, 2022
Dr. Cronin has nearly three decades of experience as a leader in clinical sleep medicine and in commercial solutions to sleep disorders.